These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11449630)

  • 1. [Trastuzumab, a new treatment approach in breast carcinoma].
    Raab G; Eiermann W
    Internist (Berl); 2001 Jun; 42(6):835-40, 842. PubMed ID: 11449630
    [No Abstract]   [Full Text] [Related]  

  • 2. Herceptin: from the bench to the clinic.
    Colomer R; Shamon LA; Tsai MS; Lupu R
    Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
    [No Abstract]   [Full Text] [Related]  

  • 3. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 4. [Trastuzumab for treatment of advanced breast cancers].
    Watanabe T; Shimizu C; Katsumata N; Saijo N
    Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab for early breast cancer: current status and future directions.
    Dinh P; de Azambuja E; Piccart-Gebhart MJ
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):707-17. PubMed ID: 17982412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 7. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
    Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
    [No Abstract]   [Full Text] [Related]  

  • 9. Herceptin raises its sights beyond advanced breast cancer.
    McNeil C
    J Natl Cancer Inst; 1998 Jun; 90(12):882-3. PubMed ID: 9637135
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody-guided drug shows encouraging activity in metastatic breast cancer.
    Cancer Biol Ther; 2009 Dec; 8(24):ii-ii. PubMed ID: 20213953
    [No Abstract]   [Full Text] [Related]  

  • 11. [Herceptin (trastuzumab)].
    Yamashiro H; Toi M
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
    Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
    J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
    Isakoff SJ; Baselga J
    J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical effectiveness of trastuzumab for breast cancer: a systematic review.
    Lewis R; Bagnall AM; Forbes C; Shirran E; Duffy S; Kleijnen J; Riemsma R; ter Riet G
    Health Technol Assess; 2002; 6(13):1-71. PubMed ID: 12137722
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab.
    Perez EA; Palmieri FM; Brock SM
    Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
    Bonneterre ME; Bonneterre J
    Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab--mechanism of action and use.
    Mir O; Berveiller P; Pons G
    N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.